Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03545165 Terminated - Prostate Cancer Clinical Trials

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Start date: April 18, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I dose escalation study with combination of 177Lu-J591 and 177Lu-PSMA-617 using a dose-fractionated regimen will be performed in patients with documented progressive metastatic CRPC. The cumulative 177Lu-J591 dose for each subject will be 2.7 GBq/m2 (73 mCi/m2) of 177Lu with 20 mg J591 and the cumulative 177Lu-PSMA-617 dose for each subject will vary (depending on the Cohort) from 3.7 GBq (100 mCi) to 18.5 GBq (500 mCi). The 177Lu-PSMA-617 dose will be escalated in up to 6 different dose levels (3+3 dose-escalation study / de-escalation design). For the phase II portion, a minimum number of 14 patients will be enrolled at MTD (including those enrolled at MTD in Phase I) and a maximum of 24.

NCT ID: NCT03543670 Completed - Prostate Cancer Clinical Trials

Evaluation of Oncoxin-Viusid® in Prostate Cancer

Start date: September 16, 2017
Phase: Phase 2
Study type: Interventional

A not randomized clinical survey was done in 25 pacients with histological diagnosis confirmed of a prostatic adenocarcinoma and hardy in hormonotherapy at the Calixto Garcia Hospital in Habana (2016-2018). Researches had as identifying goal the efecctiveness study of Oncoxin-Viusid® nutritional supplement as a support to convencional treatment. The patient were treated with habitual doses of Docetacel and 75 mg per day of supplement during and fiften day after the quimiotherapy. The rest of numbers and severety of adverse reactions were determined as well as its influences on life quality when this co-therapy is performed, the evaluation of progresion spare survival and the porcentage of recurrences.

NCT ID: NCT03543189 Active, not recruiting - Prostate Cancer Clinical Trials

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Start date: October 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety, tolerability, and effectiveness of the investigational drug nivolumab (Opdivoâ„¢) in combination with high dose radiation. Investigators also want to see if these study drugs help to delay the progression of prostate cancer.

NCT ID: NCT03541928 Recruiting - Prostate Cancer Clinical Trials

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Start date: August 2, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+ valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in previously untreated high-risk prostate cancer.

NCT ID: NCT03536065 Completed - Prostate Cancer Clinical Trials

Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery

ORIOLES
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

ORIOLES is a non-randomized, pre-post intervention study designed to improve quality of opioid prescribing and use after discharge for patients undergoing urologic surgery. The study will initially focus on a pre-defined cohort of patients undergoing radical prostatectomy. After the predefined study period for the pre-intervention arm, a three-part intervention is employed to assess the effect on opioid prescribing and use in the post-intervention arm. Pending results, the intervention may be applied to all surgeries in the department for routine clinical care.

NCT ID: NCT03535987 Completed - Prostate Cancer Clinical Trials

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

Start date: March 15, 2018
Phase:
Study type: Observational

To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.

NCT ID: NCT03533946 Terminated - Prostate Cancer Clinical Trials

Rucaparib in Nonmetastatic prOstAte With BRCAness

ROAR
Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

This is a single arm, open label, phase II trial to assess efficacy of rucaparib.

NCT ID: NCT03532308 Terminated - Prostate Cancer Clinical Trials

Nutrition and Prostate Cancer

Start date: November 21, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of Fermented Soy vs. placebo in 72 adults with localized prostate cancer prior to radical prostatectomy.

NCT ID: NCT03531099 Active, not recruiting - Prostate Cancer Clinical Trials

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

HIFUSA
Start date: October 2, 2018
Phase: Phase 3
Study type: Interventional

The percentage of malignant prostate tumors detected very early is constantly increasing and the number of well differentiated tumors, with small volume and low risk of progression increases. When a tumor of this type is identified, radical prostatectomy remains the reference treatment, but this treatment is not without side effects. Active surveillance is a strategy which aims at detecting an early development of the cancerous disease in order to propose curative treatment in a timely manner and thus improve specific survival. Patients are therefore re-evaluated each year by rectal examination, PSA (Prostate-Specific Antigen) assay. Active surveillance remains difficult to manage psychologically for both the patient and the practitioner, because of the lack of treatment on the one hand and a rate of non-curable cancers close to 50% when signs of progression trigger a radical treatment. The aim of the focal treatment HIFU (High Intensity Focused Ultrasound) is to destroy the cancer without causing side effects in contrast to radical treatments. It is in this sense that it is positioned both as an alternative to radical surgery and as an alternative to active surveillance.

NCT ID: NCT03529643 Completed - Prostate Cancer Clinical Trials

Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing RALP

Start date: May 24, 2018
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the effect of anesthetic method on the optic nerve sheath diameter in patients undergoing robot-assisted laparoscopic prostatectomy.